Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Syntex (USA) Inc.

Division of Roche

Latest From Syntex (USA) Inc.

Sale of Invention May Block Its Patenting Even If Details Are Not Disclosed, Supreme Court Concludes

America Invents Act did not alter the meaning of "on sale," unanimous court finds, so a confidential sale can qualify as prior art.

Legal Issues Intellectual Property

Genentech: Advantaged In The Middle

During Art Levinson's five-year tenure as CEO, Genentech has enjoyed its greatest period of commercial success. To get there, the company jump-started its pipeline by pouring huge sums into R&D. It was able to do so, in part, because of a put/call provision contained in its agreement with majority stakeholder Roche that, by setting a floor and a ceiling on share prices, insulated it from the usual market pressures to demonstrate earnings growth. With that protection now gone, and having given Roche an option on worldwide rights for its products, Genentech must either increase the productivity of an already impressive R&D operation or for the first time look to M&A to grow earnings, in order to achieve its goal of a five-fold sales increase by 2005. Still, Genentech's recent successes make a solid case for the viability of mid-sized companies and R&D -focused strategies in an era of consolidation.
BioPharmaceutical Strategy

Green Pharmaceuticals

A grass roots movement on the part of consumers, aided by the internet, has caused pharmaceutical companies and start-ups to look seriously at herbal medicines. Pharmaceutical companies are responding to consumer demand by acquiring or adding new divisions that sell dietary supplements, while start-ups hope to develop multi-component herbal products into larger margin drugs.
BioPharmaceutical Consumer

Green Pharmaceuticals

A grass roots movement on the part of consumers, aided by the internet, has caused pharmaceutical companies and start-ups to look seriously at herbal medicines. Pharmaceutical companies are responding to consumer demand by acquiring or adding new divisions that sell dietary supplements, while start-ups hope to develop multi-component herbal products into larger margin drugs.
BioPharmaceutical Consumer
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Roche
  • Senior Management
  • James Woody, Pres.
  • Contact Info
  • Syntex (USA) Inc.
    Phone: (415) 855-5050
    3401 Hillview Ave.
    Palo Alto, CA 94304
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register